Taysha Gene Therapies, Inc. (TSHA) Market Cap & Valuation Ratios
Taysha Gene Therapies, Inc. (TSHA) has a market cap of $1.3B and a price-to-sales ratio of 235.2, with earnings according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
TSHATaysha Gene Therapies, Inc.Follow TSHA — free
—
Price chart with a free account
- Market cap
- 1.3B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 10 Nov, in 17 days
Peers
biotechnology · nearest by market cap · trailing 12 months| Company | Mkt cap, $B | P/E | EV/Sales | EV/EBITDA | FCF yield | Rev. growth | Op. margin | ROIC |
|---|---|---|---|---|---|---|---|---|
| TSHA | 1.3 | — | 161.2 | — | -10.3% | -32% | — | — |
| OCUL | 1.4 | — | 17.3 | — | — | -8% | — | — |
| INBX | 1.4 | — | — | — | -9.6% | — | — | — |
| ORIC | 1.4 | — | — | — | -8.2% | — | — | -53% |
| DMRA | 1.3 | — | — | — | -0.5% | — | — | — |
| NKTR | 1.3 | — | 10.7 | — | — | -27% | -258% | -16% |
| LBRX | 1.2 | — | — | — | -6.6% | — | — | -174% |
| RAPP | 1.2 | — | — | — | -7.8% | — | — | -54% |
| TYRA | 1.2 | — | — | — | -9.0% | — | — | -66% |
| OMER | 1.2 | — | — | — | -5.7% | — | — | -365% |
| SNDX | 1.2 | — | 3.5 | — | — | +223% | -77% | — |
| Median of these 10 | — | 10.7 | — | -7.8% | -8% | -167% | -60% |
; EV/Sales 161.2 vs. 10.7.
Growth vs. price
each dot a company · hover or tap for valuesTaysha Gene Therapies, Inc. — questions
- What is Taysha Gene Therapies, Inc.'s market cap?
- $1.3B.
- What is Taysha Gene Therapies, Inc.'s price-to-sales ratio?
- 235.2.
Every figure on this page comes from Taysha Gene Therapies, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.